DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2198070/the-zacks-analyst-blog-highlights-adobe-astrazeneca-intel-morgan-stanley-and-eog-resources?cid=CS-ZC-FT-press_releases-2198070 Dec 14, 2023 - Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources are part of the Zacks top Analyst Blog. 0

https://www.zacks.com/stock/news/2198513/pharma-stock-roundup-pfe-issues-weak-2024-view-azn-to-buy-icosavax-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198513 Dec 15, 2023 - Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. 0

https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-lly-s-new-digital-pharmacy-nvo-abbv-s-fresh-r-d-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2206363 Jan 05, 2024 - Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases. 0

https://www.zacks.com/stock/news/2206582/astrazeneca-azn-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2206582 Jan 05, 2024 - The latest trading day saw Astrazeneca (AZN) settling at $68.38, representing a -0.58% change from its previous close. 0

https://www.zacks.com/commentary/2212742/top-research-reports-for-microsoft-procter-gamble-astrazeneca?cid=CS-ZC-FT-research_daily-2212742 Jan 19, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Procter & Gamble Company (PG) and AstraZeneca PLC (AZN). 0

https://www.zacks.com/stock/news/2223659/astrazeneca-azn-q4-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2223659 Feb 08, 2024 - Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2223512/jobless-claims-steady-mixed-q4-for-azn-hsy-and-pm?cid=CS-ZC-FT-ahead_of_wall_street-2223512 Feb 08, 2024 - We're once again reassured that employment, on a finer week-over-week scale, is not falling off a cliff. 0

https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293 Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year. 0

https://www.zacks.com/commentary/2233623/top-stock-reports-for-costco-walt-disney-astrazeneca?cid=CS-ZC-FT-research_daily-2233623 Feb 29, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), The Walt Disney Company (DIS) and AstraZeneca PLC (AZN). 0

https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322 Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use. 0